Bolt Biotherapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Bolt Biotherapeutics, Inc. (BOLT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $200.00K.
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$1.40M.
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$197.00K.
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$1.88M, a 523.87% decline year-over-year.
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$5.43M.
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$4.88M.
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$3.41M, a 223.30% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.77M, a 58.54% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.20M 10-Q · filed 2026-08-11 | -$1.40M derived: sum of 3 quarters · filed 2026-08-11 | -$3.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$1.40M 10-Q · filed 2026-05-12 | -$1.60M derived: sum of 2 quarters · filed 2026-05-12 | -$3.48M derived: sum of 3 quarters · filed 2026-05-12 | -$4.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.08M derived: sum of 2 quarters · filed 2026-03-12 | -$2.92M derived: sum of 3 quarters · filed 2026-08-11 | -$5.43M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.72M derived: sum of 2 quarters · filed 2026-08-11 | -$5.23M 10-Q · filed 2025-11-12 | -$7.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$840.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.35M 10-Q · filed 2026-08-11 | -$6.05M derived: sum of 3 quarters · filed 2026-08-11 | -$5.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$2.51M 10-Q · filed 2026-05-12 | -$5.21M derived: sum of 2 quarters · filed 2026-05-12 | -$4.76M derived: sum of 3 quarters · filed 2026-05-12 | -$3.85M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.25M derived: sum of 2 quarters · filed 2026-03-12 | -$1.34M derived: sum of 3 quarters · filed 2026-03-12 | -$4.88M 10-K · filed 2026-03-12 |
| 2024-09-30 | $444.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.36M derived: sum of 2 quarters · filed 2025-11-12 | -$2.19M 10-Q · filed 2025-11-12 | -$997.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $915.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.63M 10-Q · filed 2025-08-14 | -$1.44M derived: sum of 3 quarters · filed 2025-08-14 | -$614.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$3.54M 10-Q · filed 2025-05-12 | -$2.36M derived: sum of 2 quarters · filed 2025-05-12 | -$1.53M derived: sum of 3 quarters · filed 2025-05-12 | -$346.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.02M derived: sum of 2 quarters · filed 2025-03-24 | $3.20M derived: sum of 3 quarters · filed 2025-03-24 | -$3.41M 10-K · filed 2025-03-24 |
| 2023-09-30 | $827.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.01M derived: sum of 2 quarters · filed 2024-11-12 | -$4.60M 10-Q · filed 2024-11-12 | -$4.31M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$5.43M 10-Q · filed 2024-08-13 | -$5.14M derived: sum of 3 quarters · filed 2024-08-13 | $427.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$6.61M 10-Q · filed 2024-05-14 | -$6.32M derived: sum of 2 quarters · filed 2024-05-14 | -$756.00K derived: sum of 3 quarters · filed 2024-05-14 | -$1.45M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $5.86M derived: sum of 2 quarters · filed 2024-03-21 | $5.16M derived: sum of 3 quarters · filed 2024-03-21 | $2.77M 10-K · filed 2024-03-21 |
| 2022-09-30 | $5.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.87M derived: sum of 2 quarters · filed 2023-11-09 | $2.48M 10-Q · filed 2023-11-09 | $1.93M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$695.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.09M 10-Q · filed 2023-08-07 | -$3.64M derived: sum of 3 quarters · filed 2023-08-07 | -$521.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$2.39M 10-Q · filed 2023-05-11 | -$2.94M derived: sum of 2 quarters · filed 2023-05-11 | $174.00K derived: sum of 3 quarters · filed 2023-05-11 | $4.37M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $2.57M derived: sum of 2 quarters · filed 2023-03-29 | $6.76M derived: sum of 3 quarters · filed 2023-03-29 | $6.68M 10-K · filed 2023-03-29 |
| 2021-09-30 | $3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $7.31M derived: sum of 2 quarters · filed 2022-11-10 | $7.22M 10-Q · filed 2022-11-10 | $10.33M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $4.11M 10-Q · filed 2022-08-10 | $7.21M derived: sum of 3 quarters · filed 2022-08-10 | $7.43M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$88.00K 10-Q · filed 2022-05-12 | $3.02M derived: sum of 2 quarters · filed 2022-05-12 | $3.23M derived: sum of 3 quarters · filed 2022-05-12 | $3.33M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $3.32M derived: sum of 2 quarters · filed 2022-03-30 | $3.42M derived: sum of 3 quarters · filed 2022-03-30 | $2.88M 10-K · filed 2022-03-30 |
| 2020-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $319.00K derived: sum of 2 quarters · filed 2021-11-09 | -$221.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$438.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$540.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |